Spikimm

spikimm was founded in 2021 by truffle capital and the institut pasteur to develop human monoclonal antibodies (mabs) to prevent covid-19 infection. spk001, spikimm’s lead candidate, originally developed in the laboratory of humoral immunology (institut pasteur) headed by dr hugo mouquet, has demonstrated a potent and broad neutralization activity in vitro against sars-cov-2 and all pathogenic variants (including delta and omicron), as well as a therapeutic efficacy in vivo in mouse and hamster models. spk001 is developed as a long-acting antibody with a convenient, intramuscular administration for the prevention of covid-19 (pre-exposure prophylaxis) in immunocompromised patients unable to mount a protective antibody response after vaccination. spikimm expects to start clinical trials mid-2022.